Engrail Therapeutics is a clinical-stage pharmaceutical company focused on precision neuroscience and the development of transformational therapies for patients with neuropsychiatric and neurodevelopmental diseases. Its pipeline targets conditions with high unmet need, including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases. The company is advancing multiple programs through clinical development and is conducting an ongoing ENX-102 Phase 2 study in generalized anxiety disorder. Management states the Series B funding will propel advancement of the pipeline through multiple clinical stages and enable delivery of value-creating milestones. Engrail was incubated with support from Pivotal Life Sciences and aims to become a leader in neuroscience. Engrail Therapeutics is a neuroscience company that acquires, develops and commercializes patient-centric therapies, with lead compounds that are subtype-selective GABA-A modulators. The company is advancing a diverse pipeline, including lead assets ENX-101 and ENX-102 as well as internal preclinical programs. Earlier this year Engrail initiated a Phase 1b study for ENX-101 and a Phase 1a study for ENX-102. Engrail will use proceeds from its recent financing to accelerate clinical development and build out clinical development capabilities. The company operates via a flexible transaction model—licensing, co-development and company acquisitions—to acquire assets with validated mechanisms for nervous system diseases. Engrail was founded in 2019 and is supported by a long-term capital commitment from Nan Fung Life Sciences. Engrail Therapeutics focuses on acquiring, developing and commercializing therapies for diseases of the nervous system. Its lead pipeline asset is ENX-101, a subtype‑selective GABAA modulator that the company plans to advance clinically. Engrail applies a "science‑first" approach to identify compounds with validated mechanisms and a lower‑risk path to market. The company uses a flexible transaction model — including licensing, co‑development and company acquisitions — to build a diversified portfolio. Engrail closed a $32 million Series A to support ENX-101’s clinical development and is backed by a long‑term capital commitment from Nan Fung Life Sciences. Founded in 2019 and based in San Diego, Engrail emphasizes clinical strategy, regulatory planning, intellectual property and commercial positioning.

Total raised

$221M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2024